Corcept Therapeutics (CORT) Tops Q2 EPS by 6c; Raises Rev Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.22 -3.31%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.13, $0.06 better than the analyst estimate of $0.07. Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.53 million.
2017 revenue guidance increased by $20 million, to $145-155 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viavi Solutions (VIAV) Tops Q1 EPS by 6c; Offers Guidance
- Klaviyo, Inc. (KVYO) Tops Q3 EPS by 26c, Beats on Revenue; Offers FY26 Revenue Guidance
- Edwards Lifesciences (EW) Tops Q3 EPS by 6c; raises guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
